MannKind Corp. (MNKD)

[TREND1]

scripts part of discussion

The trend one can see in this data is very clear and must be the reason that Sanofi's executives clearly stated in their recent CC that they have reduced their expectations for Afrezza.

Investors in MannKind's stock might wish to ignore this trend, but they shouldn't. When you see a huge shortage in the normal 90 day refill data in the first cycle and then see it grow to a 65% shortage in the second cycle, you have a major problem.

At least for Sanofi, where they need to look at the $0.05 return for each dollar they are spending in marketing Afrezza. At some point they need to consider when they will stop wasting money on a marketing campaign where current indications reflect a futile result.